Primary objective:
- To compare efficacy of oral antidiabetics (OAD) combination therapy with either HOE901
insulin analogue once daily or Lispro insulin analogue at mealtime in terms of change in
HbA1c (baseline to endpoint).
Secondary objectives:
- To compare the OAD combination therapy with either HOE901 insulin analogue once daily or
Lispro insulin analogue at mealtime in terms of efficacy and safety.